Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: J Biol Inorg Chem. 2013 Dec 24;19(2):259–270. doi: 10.1007/s00775-013-1076-3

Fig. 3.

Fig. 3

a Gradient echo transversal MR images collected prior to injection and at various time points post injection of 3.0 mM ProCA1-affi342-m which is PGEylated ProCA1-affi342 targeting to HER2 in HEPES saline via tail vein. The MRI signal on the positive tumor (SKOV-3, right) exhibits significant enhancement at 24 h post injection. Blocking results confirm the specific binding of ProCA1-affi342 to HER2-positive tumors. b Enhancement changes of MRI intensity in tumors and at 24 h post injection, highest enhancement was observed. c MR imaging of contrast agent ProCA1-affi1907 targeting to EGFR specifically. d Immunostaining show HER2 targeted ProCA1-affi342 has better tumor penetration than HER2 antibodies